Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
11 Dec 2023
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217961
04 Oct 2023
// HEALTH CANADA
https://www.pharmacompass.com/pdf/news/beximco-pharmaceuticals-ltd-on-health-canada-inspection-list-39287.pdf
13 Sep 2023
// FDA
https://www.pharmacompass.com/pdf/news/beximco-pharmaceuticals-limited-fail-edqm-inspection-12511.pdf
30 Mar 2023
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216568
13 Jul 2022
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215467
20 Jan 2022
// PHARMATIMES
https://www.pharmatimes.com/news/beximco_pharma_to_manufacture_molnupiravir_for_covid-19_1386570
Details:
Molnupiravir works by interfering with the replication of virus. This prevents it from multiplying, keeping virus levels low in the body and therefore reducing the severity of the disease.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Molnupiravir-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Molnupiravir works by interfering with the replication of virus. This prevents it from multiplying, keeping virus levels low in the body and therefore reducing the severity of the disease.
Brand Name : Molnupiravir-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 09, 2021
Details:
Beximco received USFDA approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats in conditions such as tachycardia and artrial fibrillation. This marks the Company's eighth product approval for the US market.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Beximco Pharma Receives US FDA Approval for Antiarryhtmic Drug Flecainide
Details : Beximco received USFDA approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats in conditions such as tachycardia and artrial fibrillation. This marks the Company's eighth product approval...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 21, 2020
Details:
Beximco will be the exclusive supplier of the vaccine in Bangladesh and will facilitate the needs of the Government of Bangladesh by offering the opportunity for it to reserve the desired quantities for priority supply at prices to be agreed between the Government and SII.
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Brand Name: AZD1222
Study Phase: Phase IIIProduct Type: Vaccine
Recipient: Serum Institute of India
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 28, 2020
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Serum Institute of India
Deal Size : Undisclosed
Deal Type : Agreement
Beximco Pharma and Serum Institute of India Announce Intention to Cooperate on A Covid-19 Vaccine
Details : Beximco will be the exclusive supplier of the vaccine in Bangladesh and will facilitate the needs of the Government of Bangladesh by offering the opportunity for it to reserve the desired quantities for priority supply at prices to be agreed between the ...
Brand Name : AZD1222
Molecule Type : Vaccine
Upfront Cash : Undisclosed
August 28, 2020
Details:
Beximco Pharma will receive the exclusive rights to launch Mylan’s portfolio of key monoclonal antibodies to treat different types of Medical indications.
Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Large molecule
Recipient: Viatris
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 24, 2020
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Viatris
Deal Size : Undisclosed
Deal Type : Agreement
Beximco To Distribute Mylan Product Portfolio In Bangladesh
Details : Beximco Pharma will receive the exclusive rights to launch Mylan’s portfolio of key monoclonal antibodies to treat different types of Medical indications.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 24, 2020
Inspections and registrations
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?